Analytical Data
-
基因名
TWEAK/TNFSF12
-
简介
TWEAK/TNFSF12 Protein binds to FN14 and potentially TNRFSF12/APO3, weakly inducing apoptosis in certain cells. It activates NF-kappa-B, enhances angiogenesis, and stimulates endothelial cell proliferation. Furthermore, TWEAK/TNFSF12 is implicated in inflammatory cytokine induction and promotes IL8 secretion. It forms a homotrimer and interacts with the angiogenic factor AGGF1/VG5Q. TWEAK/TNFSF12 Protein, Human (HEK293, hFc) is the recombinant human-derived TWEAK/TNFSF12 protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
别名
APO3 ligand; APO3L; DR3LG; UNQ181/PRO207; TWEAK; MGC129581
-
种属
Human
-
表达系统
HEK293
-
标签
C-hFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O43508-1
-
表达区间
S43-H249
-
蛋白长度
Extracellular Domain
-
分子量
50-60 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TWEAK (TNFSF12) is a member of the tumor necrosis factor (TNF) superfamily, playing a crucial role in various biological processes, including cell proliferation, apoptosis, and inflammation. It primarily interacts with its receptor, Fn14, which is implicated in several pathophysiological conditions, such as cancer, autoimmune diseases, and tissue injury. Research on TWEAK/TNFSF12 recombinant proteins has garnered significant interest due to their potential therapeutic applications. These proteins can be utilized to study signaling pathways activated by the TWEAK-Fn14 interaction, contributing to a deeper understanding of disease mechanisms. Furthermore, recombinant TWEAK/TNFSF12 may serve as a valuable tool in drug development, providing insights into new treatments targeting diseases driven by aberrant Fn14 signaling. The modulation of immune responses and the promotion of wound healing are additional areas being explored, underscoring the protein's versatility and importance in both basic and translational research. Given the complexity of the immune system and the intertwining roles of TNF superfamily members, TWEAK/TNFSF12 stands out as a promising candidate for further investigation, with the potential to inform future therapeutic strategies addressing a range of disorders characterized by dysregulated signaling.
